Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00053287
First received: January 27, 2003
Last updated: June 9, 2010
Last verified: June 2010
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. Combining chemotherapy with thalidomide may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining fludarabine, carboplatin, and topotecan with thalidomide in treating patients who have relapsed or refractory acute myeloid leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.


Condition Intervention Phase
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Drug: carboplatin
Drug: fludarabine phosphate
Drug: thalidomide
Drug: topotecan hydrochloride
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes

Resource links provided by NLM:


Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:
  • Complete response rate [ Time Frame: 6 weeks after treatment ] [ Designated as safety issue: No ]

Enrollment: 42
Study Start Date: September 2002
Study Completion Date: March 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: carboplatin
    Carboplatin IV over 24 hours on days 1-5
    Drug: fludarabine phosphate
    Fludarabine IV over 5-10 minutes on days 1-5.
    Drug: thalidomide
    Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
    Drug: topotecan hydrochloride
    Topotecan IV continuously over 72 hours.
Detailed Description:

OBJECTIVES:

  • Determine the response rate of patients with relapsed/refractory or high-risk acute myeloid leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes treated with fludarabine, carboplatin, topotecan, and thalidomide.
  • Determine the non-hematologic toxicity profile and time to hematopoietic recovery in patients treated with this regimen.
  • Determine the effects of this regimen on changes in biologic parameters that may predict response in these patients.
  • Correlate bone marrow microvascular density before and after treatment with response in these patients.
  • Determine the prognostic value of pretreatment plasma and serum levels of vascular endothelial growth factor (VEGF) and/or the modulation of serum levels of VEGF during treatment in predicting response in these patients.

OUTLINE: Patients are stratified according to diagnosis (previously untreated acute leukemia vs other).

Patients receive fludarabine IV over 5-10 minutes and carboplatin IV over 24 hours on days 1-5 followed by topotecan IV continuously over 72 hours. Patients receive oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.

Patients with residual disease on day 16-18 may receive a second course of chemotherapy as above. Patients who achieve remission may receive a third course of chemotherapy as above as consolidation beginning 4-8 weeks after completion of prior chemotherapy.

Patients are followed monthly for 6 months.

PROJECTED ACCRUAL: A total of 40 patients (20 per stratum) will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of 1 of the following:

    • Acute myeloid leukemia meeting 1 of the following criteria:

      • Previously untreated and not a candidate for anthracycline-based chemotherapy
      • In first or second relapse or refractory
      • Secondary to chemotherapy or an antecedent hematologic disorder and treated with no more than 1 prior intensive induction regimen
    • Chronic myelogenous leukemia in blast crisis at diagnosis or after prior imatinib mesylate
    • Myelodysplastic syndromes (MDS)

      • Refractory anemia with excess blasts (RAEB) or RAEB in transformation
      • Must meet at least 1 of the following criteria:

        • Absolute neutrophil count no greater than 500/mm^3
        • Platelet or red cell transfusion-dependent after no more than 1 prior intensive induction chemotherapy
    • Acute promyelocytic leukemia

      • t(15, 17)
      • Failed prior treatment with tretinoin and arsenic
    • Relapsed disease at least 3 months after prior autologous stem cell transplantation
  • No active CNS leukemia

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-3

Life expectancy

  • At least 8 weeks

Hematopoietic

  • See Disease Characteristics

Hepatic

  • Bilirubin no greater than 2.0 mg/dL
  • AST and ALT less than 3 times upper limit of normal

Renal

  • Creatinine clearance at least 50 mL/min

Cardiovascular

  • Ejection fraction at least 40%
  • No poorly controlled cardiac disease

Pulmonary

  • No poorly controlled pulmonary disease

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile female patients must use 1 highly effective and 1 additional method of contraception for 4 weeks before, during, and for at least 4 weeks after study
  • Male patients must use effective contraception during and for 4 weeks after study
  • Willing and able to comply with the System for Thalidomide Education and Prescribing Safety (STEPS) program
  • HIV negative
  • No poorly controlled infection
  • No other active malignancy
  • No severe peripheral neuropathy

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • Prior thalidomide allowed for MDS
  • At least 5 days since prior hematopoietic growth factors
  • At least 2 weeks since prior biologic therapy
  • No prior allogeneic bone marrow transplantation

Chemotherapy

  • See Disease Characteristics
  • At least 24 hours since prior hydroxyurea

Endocrine therapy

  • At least 24 hours since prior corticosteroids

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • At least 2 weeks since prior cytotoxic anticancer therapy
  • Prior amifostine allowed for MDS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00053287

Locations
United States, Ohio
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
Study Chair: Brenda W. Cooper, MD Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Brenda Cooper, MD, Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00053287     History of Changes
Other Study ID Numbers: CWRU1902, P30CA043703, CASE-CWRU-1902, CELGENE-CWRU-1902, CASE-1902
Study First Received: January 27, 2003
Last Updated: June 9, 2010
Health Authority: United States: Federal Government

Keywords provided by Case Comprehensive Cancer Center:
adult acute promyelocytic leukemia (M3)
refractory anemia with excess blasts in transformation
refractory anemia with excess blasts
de novo myelodysplastic syndromes
recurrent adult acute myeloid leukemia
secondary acute myeloid leukemia
untreated adult acute myeloid leukemia
blastic phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
atypical chronic myeloid leukemia
myelodysplastic/myeloproliferative disease, unclassifiable
adult acute myeloid leukemia with t(8;21)(q22;q22)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with t(15;17)(q22;q12)

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Thalidomide
Fludarabine monophosphate
Vidarabine
Fludarabine
Carboplatin
Topotecan
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances

ClinicalTrials.gov processed this record on July 23, 2014